NICE_Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

The government, the NHS or the UK Health Security Agency may choose to use these treatments in a different way from that recommended in this guidance in exceptional circumstances such as:

• the widespread incidence of variants of COVID-19 to which the general population has no natural or vaccine immunity
• local or national high rates of hospitalisation with COVID-19. Guidance development process 

  This guidance does not cover molnupiravir, remdesivir or tixagevimab plus cilgavimab for treating COVID-19. NICE plans to publish technology appraisal guidance on these treatments in the future. For more information, see NICE's development page on molnupiravir, remdesivir and tixagevimab plus cilgavimab for treating COVID-19.

  This guidance updates recommendations on casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab in the therapeutics section of NICE’s rapid guideline on managing COVID-19, which contains all our latest recommendations.

  The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.